Tysabri natalizumab: Phase III data

In the 2-year, placebo-control, double-blind, international Phase III SENTINEL trial in 1,171 MS patients, the primary and secondary endpoints

Read the full 195 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE